-
LuPIN trial to recruit additional 24 patients
-
Additional patients to be treated with Veyonda? 1200 mg
-
The objective is to see whether the dose-response effect seen to date will lead to even greater response rates
-
Data from total of 56 patients expected to lay foundation for pivotal registration trial.
SYDNEY, 23 May, 2019: Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) in collaboration with St Vincent’s Hospital, Sydney, are pleased to announce that the LuPIN trial, which is investigating 177Lu-PSMA-617 in combination with Veyonda? in men with late stage metastatic castration-resistant prostate cancer (mCRPC), is to be expanded to include an additional dose cohort. This dose cohort will comprise 24 men who will be treated with Veyonda? 1200 mg daily for 10 days in combination with 177Lu-PSMA-617. The decision to proceed with the expansion was based on the encouraging results observed in respect to tolerability and interim clinical responses with the 400 and 800 mg dosages in the 32 patients enrolled in the trial to date.
For further information please download PDF attached:
Download this document
